PhRMA Members Spent $48.5 Billion On R&D In 2012
This article was originally published in The Pink Sheet Daily
A report by the industry advocacy group notes that the 31 PhRMA member companies invested 20.7% of domestic sales revenue in R&D efforts last year. The aggregate total of $48.5 billion is down slightly from 2011 and a bit further from the 2010 record amount of $50.7 billion.
You may also be interested in...
The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.
Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.
In the month ahead, a key ANDA approval could come for Viatris, while additional competition to Gilead Sciences’ Truvada for PrEP is on the way in the US following Teva and Amneal’s launches.